Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.05 EUR
91.62 M EUR
846.96 M EUR
598.52 M
About SIMCERE PHARMACEUTICAL GRP LTD
Sector
CEO
Jin Sheng Ren
Headquarters
Nanjing
Website
Founded
1995
ISIN
HK0000658531
FIGI
BBG00Y04NCF8
Simcere Pharmaceutical Group Ltd. engages in the research, development, manufacturing, and sale of pharmaceutical products. It operates through the Sale of Pharmaceutical Products and Promotion Service Income segments. The Promotion Service Income segment includes the rendering promotion service of pharmaceutical products that are not manufactured by the firm. The company was founded by Jin Sheng Ren in 1995 and is headquartered in Nanjing, China.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of S2P is 0.79 EUR — it has increased by 1.28% in the past 24 hours. Watch SIMCERE PHARMACEUTICAL GROUP LIMITED stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange SIMCERE PHARMACEUTICAL GROUP LIMITED stocks are traded under the ticker S2P.
S2P stock has fallen by −1.25% compared to the previous week, the month change is a 3.95% rise, over the last year SIMCERE PHARMACEUTICAL GROUP LIMITED has showed a −11.24% decrease.
We've gathered analysts' opinions on SIMCERE PHARMACEUTICAL GROUP LIMITED future price: according to them, S2P price has a max estimate of 1.18 EUR and a min estimate of 0.87 EUR. Watch S2P chart and read a more detailed SIMCERE PHARMACEUTICAL GROUP LIMITED stock forecast: see what analysts think of SIMCERE PHARMACEUTICAL GROUP LIMITED and suggest that you do with its stocks.
S2P stock is 1.27% volatile and has beta coefficient of 0.75. Track SIMCERE PHARMACEUTICAL GROUP LIMITED stock price on the chart and check out the list of the most volatile stocks — is SIMCERE PHARMACEUTICAL GROUP LIMITED there?
Today SIMCERE PHARMACEUTICAL GROUP LIMITED has the market capitalization of 2.03 B, it has decreased by −0.87% over the last week.
Yes, you can track SIMCERE PHARMACEUTICAL GROUP LIMITED financials in yearly and quarterly reports right on TradingView.
SIMCERE PHARMACEUTICAL GROUP LIMITED is going to release the next earnings report on Mar 20, 2025. Keep track of upcoming events with our Earnings Calendar.
S2P net income for the last half-year is 59.14 M EUR, while the previous report showed −195.48 M EUR of net income which accounts for 130.25% change. Track more SIMCERE PHARMACEUTICAL GROUP LIMITED financial stats to get the full picture.
Yes, S2P dividends are paid annually. The last dividend per share was 0.02 EUR. As of today, Dividend Yield (TTM)% is 2.61%. Tracking SIMCERE PHARMACEUTICAL GROUP LIMITED dividends might help you take more informed decisions.
SIMCERE PHARMACEUTICAL GROUP LIMITED dividend yield was 2.61% in 2023, and payout ratio reached 58.03%. The year before the numbers were 1.51% and 42.39% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 10, 2024, the company has 7.03 K employees. See our rating of the largest employees — is SIMCERE PHARMACEUTICAL GROUP LIMITED on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SIMCERE PHARMACEUTICAL GROUP LIMITED EBITDA is 141.50 M EUR, and current EBITDA margin is 12.93%. See more stats in SIMCERE PHARMACEUTICAL GROUP LIMITED financial statements.
Like other stocks, S2P shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SIMCERE PHARMACEUTICAL GROUP LIMITED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SIMCERE PHARMACEUTICAL GROUP LIMITED technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SIMCERE PHARMACEUTICAL GROUP LIMITED stock shows the sell signal. See more of SIMCERE PHARMACEUTICAL GROUP LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.